In Depth 16 Dec 2025 Biotech in 2025: A retrospective Take a look back into biotech in 2025 as the year is closing – from GLP-1s to radiopharmaceuticals and neuroplastogens. December 16, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 24 Sep 2025 Eli Lilly’s strategy in motion: Beyond diabetes and obesity Delve into a biopharma giant’s strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. September 24, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 3 Sep 2025 Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand As radiopharma is gaining momentum, read our interview with Dr. Delpassand, the CEO of RadioMedix’s, an established company of the field. September 3, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2025 Radiopharma’s new wave: Nuclidium and Actithera raise the stakes Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms. July 10, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues. February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2025 ITM-11 succeeds in phase 3: The first big win for radiopharma? Discover ITM and its cancer candidate ITM-11, as it brings one of the first big wins the radiopharmaceutical sector awaits. January 28, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 26 Sep 2024 The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation. September 26, 2024 - 14 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 23 Aug 2024New German biotech spins out to develop radiotherapeutics While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company August 23, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Podcast 5 Jul 2024The radiotherapeutics boom The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field. July 5, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 13 Jun 2023 ITM follows €255M investment round by opening new facility After a recent funding announcement, Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has opened its new production facility for therapeutic radionuclides in Neufahrn near Munich, Germany. ITM’s new facility is the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies. Due to its medical properties, lutetium-177 has […] June 13, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2023 How cancer cells repair DNA damage from radiotherapy A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […] March 17, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 New drug could replace current standard for treating brain cancer Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […] January 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email